Image_3_Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2.tif

Therapeutic antibodies with potent efficacy to the Omicron variants are urgently demanded.</p>Methods<p>Utilizing the rapid antibody discovery platform, Berkeley Lights Beacon, we isolated two monoclonal neutralizing antibodies, 2173-A6 and 3462-A4.

These antibodies were isolated from individuals who recently recovered from Omicron infections.</p>Results<p>Both antibodies, 2173-A6 and 3462-A4, demonstrated high affinity for the RBD and effectively neutralized pseudoviruses from various Omicron lineages, including BA.4/5, XBB.1.16, XBB.1.5, and EG.5.1. This neutralization was achieved through binding to identical or overlapping epitopes.</p>Discussion<p>The use of the Beacon platform enabled the rapid isolation and identification of effective neutralizing antibodies within less than 10 days.